Cancer nanomedicine

The field of cancer nanomedicine seeks to overcome the inherent shortcomings of conventional cancer diagnostics and therapies. Yet despite the surge of interest in and attractive attributes of nanotechnologies, challenges remain in their clinical translation, prompting some to argue that they have n...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatia, Sangeeta N., Chen, Xiaoyuan, Dobrovolskaia, Marina A., Lammers, Twan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358926/
https://www.ncbi.nlm.nih.gov/pubmed/35941223
http://dx.doi.org/10.1038/s41568-022-00496-9
_version_ 1784764032608108544
author Bhatia, Sangeeta N.
Chen, Xiaoyuan
Dobrovolskaia, Marina A.
Lammers, Twan
author_facet Bhatia, Sangeeta N.
Chen, Xiaoyuan
Dobrovolskaia, Marina A.
Lammers, Twan
author_sort Bhatia, Sangeeta N.
collection PubMed
description The field of cancer nanomedicine seeks to overcome the inherent shortcomings of conventional cancer diagnostics and therapies. Yet despite the surge of interest in and attractive attributes of nanotechnologies, challenges remain in their clinical translation, prompting some to argue that they have not yet reached their true potential. In this Viewpoint article, we asked four experts for their opinions on how we can fulfil the great promise of nanomedicine for the detection, diagnosis and treatment of patients with cancer.
format Online
Article
Text
id pubmed-9358926
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-93589262022-08-09 Cancer nanomedicine Bhatia, Sangeeta N. Chen, Xiaoyuan Dobrovolskaia, Marina A. Lammers, Twan Nat Rev Cancer Viewpoint The field of cancer nanomedicine seeks to overcome the inherent shortcomings of conventional cancer diagnostics and therapies. Yet despite the surge of interest in and attractive attributes of nanotechnologies, challenges remain in their clinical translation, prompting some to argue that they have not yet reached their true potential. In this Viewpoint article, we asked four experts for their opinions on how we can fulfil the great promise of nanomedicine for the detection, diagnosis and treatment of patients with cancer. Nature Publishing Group UK 2022-08-08 2022 /pmc/articles/PMC9358926/ /pubmed/35941223 http://dx.doi.org/10.1038/s41568-022-00496-9 Text en © Springer Nature Limited 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Viewpoint
Bhatia, Sangeeta N.
Chen, Xiaoyuan
Dobrovolskaia, Marina A.
Lammers, Twan
Cancer nanomedicine
title Cancer nanomedicine
title_full Cancer nanomedicine
title_fullStr Cancer nanomedicine
title_full_unstemmed Cancer nanomedicine
title_short Cancer nanomedicine
title_sort cancer nanomedicine
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358926/
https://www.ncbi.nlm.nih.gov/pubmed/35941223
http://dx.doi.org/10.1038/s41568-022-00496-9
work_keys_str_mv AT bhatiasangeetan cancernanomedicine
AT chenxiaoyuan cancernanomedicine
AT dobrovolskaiamarinaa cancernanomedicine
AT lammerstwan cancernanomedicine

Ejemplares similares